Anika Therapeutics Inc (ANIK)vsMerck & Company Inc (MRK)
ANIK
Anika Therapeutics Inc
$14.48
-2.10%
HEALTHCARE · Cap: $191.73M
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 56468% more annual revenue ($65.77B vs $116.26M). MRK leads profitability with a 13.6% profit margin vs -9.5%. ANIK appears more attractively valued with a PEG of 3.51. MRK earns a higher WallStSmart Score of 50/100 (D+).
ANIK
Hold38
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.4%
Fair Value
$32.46
Current Price
$14.48
$17.98 discount
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -8.3% — below average capital efficiency
Earnings declined 50.5%
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ANIK
The strongest argument for ANIK centers on Price/Book, Altman Z-Score, Debt/Equity. Revenue growth of 13.2% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : ANIK
The primary concerns for ANIK are Market Cap, PEG Ratio, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
ANIK profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.20 — expect wider price swings.
ANIK is growing revenue faster at 13.2% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 38/100). ANIK offers better value entry with a 68.4% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Anika Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?